[go: up one dir, main page]

AR026022A1 - METHOD FOR THE TREATMENT OF OBESITY - Google Patents

METHOD FOR THE TREATMENT OF OBESITY

Info

Publication number
AR026022A1
AR026022A1 ARP000105369A ARP000105369A AR026022A1 AR 026022 A1 AR026022 A1 AR 026022A1 AR P000105369 A ARP000105369 A AR P000105369A AR P000105369 A ARP000105369 A AR P000105369A AR 026022 A1 AR026022 A1 AR 026022A1
Authority
AR
Argentina
Prior art keywords
obesity
treatment
solvatofarma
animal
pharmaceutically acceptable
Prior art date
Application number
ARP000105369A
Other languages
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR026022A1 publication Critical patent/AR026022A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Método para el tratamiento de la obesidad que comprende administrar a un animal que necesite del mismo, un compuesto de formula (1) o una sal o solvatofarmacéuticamente aceptable del mismo. Los métodos para la supresion del apetito, para causarpérdi da de peso, para prevenir el aumento de peso, para afectarpreferencialmente la composicion grasa del cuerpo, para inhibir el antojo del alimento, o para mantener el peso bajo también se describen.Method for the treatment of obesity which comprises administering to an animal in need thereof, a compound of formula (1) or a pharmaceutically acceptable salt or solvatofarma thereof. Methods for appetite suppression, to cause weight loss, to prevent weight gain, to preferentially affect the body's fat composition, to inhibit food cravings, or to keep weight low are also described.

ARP000105369A 1999-10-13 2000-10-12 METHOD FOR THE TREATMENT OF OBESITY AR026022A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
AR026022A1 true AR026022A1 (en) 2002-12-26

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105369A AR026022A1 (en) 1999-10-13 2000-10-12 METHOD FOR THE TREATMENT OF OBESITY

Country Status (6)

Country Link
EP (1) EP1220673A2 (en)
JP (1) JP2003511410A (en)
AR (1) AR026022A1 (en)
AU (1) AU7750100A (en)
PE (1) PE20010744A1 (en)
WO (1) WO2001026641A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414518A4 (en) 2001-08-08 2009-01-21 Kevin R Orton Apparatus and method for electrically conductive weight reduction
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
PT2316456T (en) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
JP2011506298A (en) * 2007-12-05 2011-03-03 アストラゼネカ アクチボラグ Novel compound IV
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Methods for treating visceral fat conditions
CA2726646A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab New compounds vii
JP6196041B2 (en) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド Methods for providing weight loss therapy in patients with major depression
RS60682B1 (en) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
WO1999025355A1 (en) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Method of treating addiction to nicotine products
NZ529316A (en) * 1998-01-21 2004-05-28 Glaxo Group Ltd Pharmaceutically active morpholinol
MA26693A1 (en) * 1998-09-28 2004-12-20 Glaxo Group Ltd COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
AU7750100A (en) 2001-04-23
JP2003511410A (en) 2003-03-25
WO2001026641A2 (en) 2001-04-19
EP1220673A2 (en) 2002-07-10
WO2001026641A3 (en) 2002-01-10
PE20010744A1 (en) 2001-07-23

Similar Documents

Publication Publication Date Title
MX2024007720A (en) Lipids for lipid nanoparticle delivery of active agents.
KR950010890A (en) Treatment of Menopause Syndrome
CY1105000T1 (en) USE OF SPINOSADI OR A COMPOSITION OF SPINOSADI CONTENT
CO6331425A2 (en) COMPOSITIONS THAT INCLUDE N- (3,4-DIFLUORO-2- (2-FLUORO-4-IODOFENILAMINO) 6-METOXIFENIL) -1- (2,3-DIHYDROXIPROXIPROPIL) CICLOPROPAN-1-SULFAMIDA
AR030933A1 (en) TRIAZOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DOP2004001052A (en) 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 INHIBITORS AMINO
KR930003912A (en) Congestive Heart Failure Treatment Cure
CL2023000196A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of use thereof
CO5251429A1 (en) DERIVATIVES OF TER-BUTIL- (7-METHYL-IMIDAZO (1,2-A) PIRIDIN-3- IL) -AMINE PROCEDURE FOR PREPARATION, DRUGS THAT CONTAIN THEM, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS THAT L
KR930019637A (en) Imidazole derivatives having biphenylsulfonylurea or biphenylsulfonylurethane side chains, preparation method and use thereof
PA8591701A1 (en) PIRROLOPIRIMIDINE DERIVATIVES
CY1109242T1 (en) THERAPEUTIC AGENTS USEFUL FOR PAIN TREATMENT
AR026022A1 (en) METHOD FOR THE TREATMENT OF OBESITY
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CR7510A (en) DERIVATIVES OF [1-4] DIAZEPINO [6,7,1-iJ)] QUINOLONA AS ANTIPSYTIC AGENTS AND AGAINST OBESITY
CY1106763T1 (en) PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
TR200102646T2 (en) Treating eating disorders.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
AR039190A1 (en) BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND
TR200101633T2 (en) Pharmaceutical composition
CO5200778A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A THERAPEUTICALLY EFFECTIVE AMOUNT OF B ENZIMIDAZOL, ADMINISTERED TO PREVENT AND TREAT CANCER AND INHIBIT METASTASIS
AR014964A1 (en) DERIVATIVES OF INDOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AGENTS TO REDUCE INTRAOCULAR PRESSURE, TREAT GLAUCOMA AND OCULAR HYPERTENSION, USE THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR MANUFACTURING OF THESE COMPOSITIONS
RU2019121690A (en) DEXMEDETOMIDINE OR METHOMIDINE FOR USE FOR THE TREATMENT OF SEPARATION ANXIETY IN DOGS
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer